Janssen 54767414MMY3021, A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

July 25, 2019
https://clinicaltrials.gov/ct2/show/NCT03901963
Cancer - Myeloma
Principal Investigator: Edward M Peres, MD
Myeloma
Accepting Participants
(313)916-1784